Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 0.00 | -0.26 | 0.10 |
| FCF Yield | -10.90% | -12.00% | -10.74% | -8.14% |
| EV / EBITDA | -5.20 | -3.50 | -6.62 | -5.00 |
| Quality | ||||
| ROIC | -11.17% | -9.26% | -8.79% | -8.03% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.88 | 0.89 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -7.55% | -0.55% | -31.96% | 45.42% |
| Safety | ||||
| Net Debt / EBITDA | 2.09 | 3.02 | 1.90 | 2.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,653.46 | -6,392.60 | 0.00 | -5,006.25 |